Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
// Liu Yang 1 , Dongdong Fang 1 , Huijun Chen 2 , Yiyu Lu 1 , Zheng Dong 3 , Han-Fei Ding 4 , Qing Jing 5 , Shi-Bing Su 1,6 and Shuang Huang 1,6,7 1 Research Center for Traditional Chinese Medicine Complexity System, Shanghai University of Traditional Chinese Medicine, Shanghai, China 2 Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China 3 Department of Anatomy and Cell Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA, USA 4 Cancer Center, Georgia Regents University, Augusta, GA, USA 5 Department of Cardiology, Changhai Hospital, Shanghai, China 6 E-institute of Shanghai Municipal Education Committee, Shanghai University of Traditional Chinese Medicine, Shanghai, China 7 Department of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA, USA Correspondence to: Shuang Huang, email: // Shi-Bing Su, email: // Keywords : CCNE1, Cdk2, ovarian cancer, tumor development Received : April 01, 2015 Accepted : June 12, 2015 Published : June 23, 2015 Abstract CCNE1 gene amplification is present in 15-20% ovary tumor specimens. Here, we showed that Cyclin E1 (CCNE1) was overexpressed in 30% of established ovarian cancer cell lines. We also showed that CCNE1 was stained positive in over 40% of primary ovary tumor specimens regardless of their histological types while CCNE1 staining was either negative or low in normal ovary and benign ovary tumor tissues. However, the status of CCNE1 overexpression was not associated with the tumorigenic potential of ovarian cancer cell lines and also did not correlate with pathological grades of ovary tumor specimens. Subsequent experiments with CCNE1 siRNAs showed that knockdown of CCNE1 reduced cell growth only in cells with inherent CCNE1 overexpression, indicating that these cells may have developed an addiction to CCNE1 for growth/survival. As CCNE1 is a regulatory factor of cyclin-dependent kinase 2 (Cdk2), we investigated the effect of Cdk2 inhibitor on ovary tumorigenecity. Ovarian cancer cells with elevated CCNE1 expression were 40 times more sensitive to Cdk2 inhibitorSNS-032 than those without inherent CCNE1 overexpression. Moreover, SNS-032 greatly prolonged the survival of mice bearing ovary tumors with inherent CCNE1 overexpression. This study suggests that ovary tumors with elevated CCNE1 expression may be staged for Cdk2-targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“CCNE1 is abnormally expressed in various tumor types [11, 22].”
BackgroundMelanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371 · cited 1×
“Some of the well-established examples on oncogene addiction include amplification of HER2 in breast cancer [27], mutated EGFR in non-small cell lung cancer [28], mutated BRAF in melanomas [29] and BcrAbl in chronic myeloid leukemia [30, 31].”
BackgroundRational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083 · cited 1×
“Some of the well-established examples on oncogene addiction include amplification of HER2 in breast cancer [27], mutated EGFR in non-small cell lung cancer [28], mutated BRAF in melanomas [29] and BcrAbl in chronic myeloid leukemia [30, 31].”
Background
Cited by
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Sicinski, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 564
Genome-Informed Targeted Therapy for Osteosarcoma
Sayles, L. C., Breese, M. R., Koehne, A. L., Leung, S. G., Lee, A. G., Liu, H.-Y., Spillinger, A., Shah, A. T., Tanasa, B., Straessler, K., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1152 · Cited by 452
“CDK2 inhibitors have been proposed as targeted therapy for Cyclin E–amplified tumors (35, 36).”
BackgroundTargeting CDK2 in cancer: challenges and opportunities for therapy
Tadesse, S., Anshabo, A. T., Portman, N., Lim, E., Tilley, W., Caldon, C. E., & Wang, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.001 · Cited by 333
Pathogenesis and heterogeneity of ovarian cancer
Kroeger, P. T., & Drapkin, R. (2017) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000340 · Cited by 314
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01469 · Cited by 276
Metadata
- Authors
- Yang, L., Fang, D., Chen, H., Lu, Y., Dong, Z., Ding, H.-F., Jing, Q., Su, S.-B., & Huang, S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-06-23
- Volume
- 6
- Issue
- 25
- Pages
- 20801-20812
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2129334913
- Cited by
- 98
- References
- 3
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.